Aug 31 (Reuters) - Progenics Pharmaceuticals Inc
* Progenics Pharmaceuticals provides update on timing of NDA submission for Azedra
* Progenics - co was notified that commercial drug product manufacturing facility for Azedra needs more time to prepare for pre-approval inspection by FDA
* Progenics Pharma - data from pivotal phase 2b study of azedra will be presented at 5th International Symposium On Pheochromocytoma & Paraganglioma on Sept. 1
* Progenics - under rolling submission, co has submitted all portions of NDA to FDA, except for notification of pre-approval inspection readiness
* Progenics Pharmaceuticals Inc - interactions with FDA on Azedra rolling submission continue to be "positive and productive"
* Progenics Pharmaceuticals - manufacturer has indicated it will need up to a few months to complete preparation for pre-approval inspection by FDA Source text for Eikon: Further company coverage: